<DOC>
	<DOC>NCT01271439</DOC>
	<brief_summary>This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal carcinoma. Besides, to figure out the relationship between patient outcome and EGFR gene copy number, expression and mutation.</brief_summary>
	<brief_title>Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic diagnosis of nasopharyngeal carcinoma Range from 18～69 years old T34，N02，M0 (AJCC 2009) KPS ≥ 80 Nonmetastatic diseases WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L ALT or AST ＜ 1.5×ULN、bilirubin ＜ 1.5×ULN 0Serum creatinine ＜ 1.5×ULN Distance metastases Previously treated (surgery，chemotherapy, radiation therapy，EGFR targeted therapy or immunotherapy) Second malignancy within 5 years Precious therapy with an investigational agent Uncontrolled seizure disorder or other serious neurologic disease ≥ Grade Ш allergic reaction to any drug including in this study Clinically significant cardiac or respiratory disease Creatinine clearance &lt; 30ml/min Drug or alcohol addition Do not have full capacity for civil acts Severe complication, active infection Concurrent immunotherapy or hormone therapy for other diseases Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>